A Open-label, Long-term Extension Study of KUC-7483 in Patients With Overactive Bladder.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2010
At a glance
- Drugs Ritobegron (Primary)
- Indications Overactive bladder
- Focus Adverse reactions
- Sponsors Kissei Pharmaceutical
- 26 Jul 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 05 Nov 2009 New trial record